Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024
Rhea-AI Summary
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer treatment, has announced its upcoming second quarter 2024 financial results and business update conference call. The event is scheduled for Tuesday, August 13, 2024, at 8:00 a.m. Eastern Time. Investors and interested parties can access the call via phone or webcast. The webcast will be available on the company's website for approximately 90 days following the conference call.
Positive
- None.
Negative
- None.
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
When will Mersana Therapeutics (MRSN) report its Q2 2024 earnings?
What time is Mersana Therapeutics' (MRSN) Q2 2024 earnings call?
How can I access Mersana Therapeutics' (MRSN) Q2 2024 earnings call?
Where can I find the replay of Mersana Therapeutics' (MRSN) Q2 2024 earnings call?
